At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 144 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
BIA 2-093 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 in Controlling Refractory Partial Seizures When Added to Ongoing Therapy
In Brief
A Phase 2 clinical trial evaluating BIA 2-093 and Placebo for Epilepsy. Completed, enrolled 144 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the efficacy of BIA 2 093 in the treatment of epileptic patients with refractory simple or complex partial seizures with or without secondary generalization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPortugal
Collaborators--
Timeline
Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2002
Primary CompletionNov 2002
First PostedJun 2014
TodayJul 2026
First PostedJun 23, 2014
Enrollment StartApr 1, 2002
Primary CompletionNov 1, 2002
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.0 years ago
Interventions
BIA 2-093drug
BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
Placebodrug
Placebo tablets administered orally